{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.8131","value":"2.119"},{"groupId":"OG001","spread":"0.5735","value":"2.013"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"479"}],"units":"Participants"}],"title":"Physical Functioning, n=244,479"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.2427","value":"2.341"},{"groupId":"OG001","spread":"0.8810","value":"1.590"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"479"}],"units":"Participants"}],"title":"Role Functioning, n=244,479"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.1218","value":"-0.011"},{"groupId":"OG001","spread":"0.7685","value":"-0.870"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"243"},{"groupId":"OG001","value":"478"}],"units":"Participants"}],"title":"Emotional Functioning, n=243,478"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.2105","value":"-0.020"},{"groupId":"OG001","spread":"0.7952","value":"-0.842"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"243"},{"groupId":"OG001","value":"478"}],"units":"Participants"}],"title":"Cognitive Functioning, n=243,478"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.2449","value":"5.557"},{"groupId":"OG001","spread":"0.8633","value":"4.445"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"243"},{"groupId":"OG001","value":"478"}],"units":"Participants"}],"title":"Social Functioning, n=243,478"}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"479"}],"units":"Participants"}],"description":"EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale (global health status, QoL), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Five functional scales had total 15 items (physical-5, role-2, cognitive-4, emotional-2, and social-2). Each functional scales score was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus \\[average score minus 1\\] divided by 3\\*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher (\"better\") level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).","dispersionType":"Standard Error","groups":[{"description":"Participants received placebo matching niraparib 300 milligram (mg) (3×100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kilogram \\[kg\\] and Baseline platelet count \\>=150,000 per microliter \\[μL\\]) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"OG000","title":"Placebo"},{"description":"Participants received niraparib 300 mg (3×100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kg and Baseline platelet count \\>=150,000 per μL) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"OG001","title":"Niraparib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1, Pre-dose) and Up to Week 24","title":"Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}